These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Anton PM; O'Brien M; Kokkotou E; Eisenstein B; Michaelis A; Rothstein D; Paraschos S; Kelly CP; Pothoulakis C Antimicrob Agents Chemother; 2004 Oct; 48(10):3975-9. PubMed ID: 15388461 [TBL] [Abstract][Full Text] [Related]
25. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Clutter DS; Dubrovskaya Y; Merl MY; Teperman L; Press R; Safdar A Antimicrob Agents Chemother; 2013 Sep; 57(9):4501-5. PubMed ID: 23836168 [TBL] [Abstract][Full Text] [Related]
26. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer. Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587 [TBL] [Abstract][Full Text] [Related]
27. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. Johnson AP; Wilcox MH J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382 [TBL] [Abstract][Full Text] [Related]
28. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis. Hostler CJ; Chen LF Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070 [TBL] [Abstract][Full Text] [Related]
29. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Zar FA; Bakkanagari SR; Moorthi KM; Davis MB Clin Infect Dis; 2007 Aug; 45(3):302-7. PubMed ID: 17599306 [TBL] [Abstract][Full Text] [Related]
30. Fidaxomicin--the new drug for Clostridium difficile infection. Vaishnavi C Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840 [TBL] [Abstract][Full Text] [Related]
31. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357 [TBL] [Abstract][Full Text] [Related]
32. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318 [TBL] [Abstract][Full Text] [Related]
33. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627 [TBL] [Abstract][Full Text] [Related]
34. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT; Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269 [TBL] [Abstract][Full Text] [Related]
35. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319 [TBL] [Abstract][Full Text] [Related]
36. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148 [TBL] [Abstract][Full Text] [Related]
37. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327 [TBL] [Abstract][Full Text] [Related]
38. Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study. Nguyen CT; Li J; Anders S; Garcia-Diaz J; Staffeld-Coit C; Hand J Transpl Infect Dis; 2018 Jun; 20(3):e12867. PubMed ID: 29512244 [TBL] [Abstract][Full Text] [Related]
39. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. Lam SW; Bass SN; Neuner EA; Bauer SR Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633 [TBL] [Abstract][Full Text] [Related]
40. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]